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JOINT LUBRICATION: HOW DOES NATURE DO IT?
J. Klein. Weizmann Inst. of Sci., Rehovot, Israel
The articular cartilage layers coating the major synovial joints such as
hips or knees are remarkable constructs. They not only support a wide
range of stresses and impacts but, inparticular, healthy cartilage surfaces
sliding past each other exhibit extremely low levels of friction under
physiologically-high pressures. This is a lubricity which no man-made
surfaces can emulate. A detailed molecular-level understanding of this
could beneﬁt treatments of osteoarthritis (OA), as well as improved
prosthetic joint implants, where low friction may suppress wear debris
formation and the associated periprosthetic osteolysis. The relation of
cartilage friction to OA development is especially intriguing: while tra-
ditionallyOAwas considereda ‘wearand tear’disease, there is increasing
evidence that protease production by chondrocytes within the cartilage
in response to shear stresses may play an important role in the cartilage
degradation and progress of OA. Since such shear stresses are a direct
consequence of friction on the articulating cartilage surface, it is clear
that insight into ‘how nature does it’ would be of considerable value in
manipulating the friction. But despite decades of study, such under-
standing remains elusive. Any insightmust, ﬁrst and foremost, be able to
account for the low friction (CoF down to ca. 0.001) at the high pressures
(which can reach 100 atm or higher) of the joints. Hydrodynamic effects
have been considered as a lubrication mechanism, but it is likely that a
mixed regime including both ﬂuid-ﬁlm and boundary lubrication
operates, and the crucial issue concerns the nature of the boundary layer
at the cartilage surface. Three quite different components of articular
cartilage and of the synovial ﬂuid surrounding it have each, separately,
been widely invoked as the boundary molecule responsible for the
remarkable lubrication of joints: Hyaluronan (HA), a linear poly-
saccharide; lubricin a proteoglycan; and phospholipids. Direct meas-
urements, however, indicate that none of these can, by itself, explain the
low friction of the cartilage surface at the high pressures characteristic of
the major joints. Over the past decade, hydration lubrication has
emerged as a newparadigm for extreme lubrication in aqueous systems,
which may underlie also the very efﬁcient boundary lubrication of car-
tilage. According to this, the hydration shells formed by dipolar water
molecules about charges in water (such as ions or zwitterions) may be
very tenaciously attached, so that they resist being squeezed out even
under large pressures. At the same time, these same hydration shells
maybehaveveryﬂuidlyunder shear. This resistance topressure together
with low-friction sliding makes them into excellent lubrication ele-
ments. Very recently, we discovered that HA which is attached to a
surface - to resemble its conﬁguration at the outer cartilage surface -may
complex with phosphatidylcholines (PCs), lipids that are ubiquitous in
synovial joints, to form robust boundary layers. These layers act syn-
ergistically to provide the very low friction (mz 0.001) characteristic of
cartilage, at the highest physiological pressures, and contrast with sur-
face-attachedHAon its own,which leads to considerably higher friction.
The very low friction is ultimately due to the phosphocholine groups
exposed by the HA/PC surface complexes; these groups are known to be
strongly and highly-hydrated, and so they lubricate via the mechanism
described above. Our results thus point to a scenario where HA, PCs and1063-4584/$ e see front matterlubricin, each with a very different role, act together synergistically to
reduce frictionof cartilage in articulating joints. Hyaluronan, anchored at
the outer surface of articular cartilage by lubricin molecules (which are
known to be present in the outer superﬁcial zone), complexes with joint
phosphatidylcholines to provide the extreme boundary lubrication of
synovial joints via the hydration-lubrication mechanism.
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LUBRICIN AND ITS POTENTIAL AS AN OA THERAPY
C.R. Flannery. Genzyme, a Sanoﬁ Company, Framingham, MA, USA
Originally identiﬁed as a lubricating component of synovial ﬂuid, the
mucinous glycoprotein lubricin is now recognized to be a major chon-
droprotective macromolecule which localizes to, and affords boundary
lubrication of, articular cartilage surfaces. Lubricin is synthesized in the
joint by cells of the synovial lining, as well as by tendon and meniscal
cells, in addition to its expression by superﬁcial zone chondrocytes
(wherefrom it was initially described as ‘superﬁcial zone protein’, or
SZP). Genetic ablation of lubricin synthesis in mice, or in humans with a
rare autosomal recessive disorder, CACP syndrome, results in accel-
erated cartilage damage and joint failure, with associated non-inﬂam-
matory synovial hypercellularity/thickening and subintimal capsular
ﬁbrosis. In addition, data from joint injury models have demonstrated
alterations in lubricin expression, as well as elevated cartilage friction
levels which may be attenuated by lubricin restitution.
Based in part on the aforementioned ﬁndings, several independent
laboratories have explored the potential utility of lubricin supple-
mentation for the treatment of OA. Such investigations have included
augmentation via intraarticular injections of natural or recombinant
lubricin molecules, and these campaigns have been successful in pre-
clinical (rodent) models of OA, resulting in reduced cartilage damage
and OA scores. Additional beneﬁcial consequences of lubricin admin-
istration have also been demonstrated, including protection against
chondrocyte apoptosis, and evidence for symptom (pain) modiﬁcation
as measured by normalization of differential weight-bearing, or gait
asymmetry, between diseased and contralateral limbs.
An important consideration for such therapeutic strategies relates to
the ‘residence time’ of exogenously applied lubricin within the joint.
Whereas soluble molecules present in synovial ﬂuid exhibit a relatively
rapid rate of clearance, lubricin bound to tissue (i.e. cartilage) surfaces
can exhibit a greater longevity, and maximizing lubricin retention and
exposure within the joint would seem to bear high importance for
successful translational applicability. In this regard, other opportunities
for providing enduring lubricin levels may include gene therapy-based
approaches wherein lubricin is delivered via, for example, viral-based
vectors, and for which preclinical proof-of-principle studies have also
recently been reported.
The ultimate clinical development of lubricin supplementation thera-
pies will be dependent on a number of critical factors. Of high impor-
tance is the technical capability and capacity to produce validated and
cost-effective materials (i.e. recombinant lubricin molecules). Equally
necessary are contingencies for identifying a responsive patient pop-
ulation, and establishing appropriate, clinically meaningful and regu-
latory agency-approved endpoints which can be robustly measured. As
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safety pharmacology evaluations should indicate a low level of risk
associated with dosing and administration procedures, thereby
enhancing the rationale for investing in such a modality for the treat-
ment of OA.
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IMPACT OF KNEE OA ON MEETING PHYSICAL ACTIVITY GUIDELINES
D.K. White. Univ. of Delaware, Newark, DE, USA
Purpose: Physical activity has irrefutable health beneﬁts. For people
with knee osteoarthritis (OA), pain is a well-known cause of functional
limitation in people with knee (OA), however it is unclear whether it is
also responsible for a reduction in physical activity behaviors. Anec-
dotally, pain is thought to be responsible for less physical activity. We
will review the literature investigating whether knee OA-related pain is
in fact a risk factor for less physical activity. As well, we will investigate
whether physical activity is responsible for changes in pain.
Methods: We will summarize studies of objectively measured physical
activity among people with knee OA from well-established cohort
studies. We will also review the association of physical activity with
knee pain and function from clinical intervention trials and observa-
tional studies among people with knee OA.
Results: Physical activity guidelines, i.e., participation in at least 150
minutes of moderate to vigorous physical activity (MVPA), was met by
12.9% of men and 7.7% of women from the Osteoarthritis initiative.
However, a similarly low proportion met guidelines from the National
Health and Nutrition Examination Survey. Furthermore, a similar pro-
portion of people with and without knee pain met guidelines from daily
walking from the Multicenter Osteoarthritis (MOST) study. These data
suggest the presence of knee painmay not fully account for low levels of
physical activity in knee OA. Clinical trials incorporating physical
activity interventions, such as aerobic walking, reduce knee pain. We
have previously reported a strong association between walking at least
6,000 steps/day and the prevention of functional limitation 2 years later
in the MOST study.
Conclusions: Knee pain alone may not lead to a reduction in physical
activity among people with knee OA. However, the beneﬁts of adopting
a physically active lifestyle include reducing existing knee pain and
preventing the development of functional limitation in knee OA.
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THE AGING PROCESS AND EPIGENETICS: RELATIONSHIP WITH OA
L. Reynard. Inst. of Cellular Med., Newcastle Univ., Newcastle upon Tyne,
United Kingdom
Purpose: The term ‘epigenetics’ refers to heritable changes in gene
expression or phenotype that occur without changes to the underlying
DNA sequence. There are three mechanisms of epigenetic gene regu-
lation; DNA methylation, post-translational modiﬁcations of histone
proteins, and non-coding RNAs (ncRNAs) such as microRNAs. They
regulate gene expression either by affecting gene transcription (DNA
methylation, histone modiﬁcations and some ncRNAs) or by acting
post-transcriptionally, leading to changes in the levels of the encoded
protein (e.g. microRNAs). Epigenetic patterns are both plastic, especially
during development and cell differentiation when they undergo
dynamic changes, and stable, allowing cellular identify to be main-
tained during mitotic cell divisions. Furthermore, epigenetic changes
occur in response to environmental factors including diet, exercise and
smoking, and during aging, leading to the suggestion that a possible
mechanism for the late onset of common human diseases is the age-
related loss of normal epigenetic control. Several studies have indicated
that epigenetic changes contribute to the alterations in gene expression
and phenotype observed during aging and in OA. The majority of these
studies have been performed in cartilage due to its lack of cell hetero-
geneity, and in the case of DNA methylation, have concentrated on the
promoter regions of genes that are dysregulated in OA. In this talk, I will
begin by giving an overview of the age- and OA-related epigenetic
changes observed in musculoskeletal tissues. I will then present the
ﬁndings from our recent genome-wide methylation analysis of aged
and osteoarthritic cartilage. I will ﬁnish by discussing areas for future
research into epigenetics and aging of the musculoskeletal system, and
in particular, given that OA is a disease of the whole joint, the potential
to extend these analyses to other joint tissues.I-5
UPDATE ON CRYSTALS AND OA
A.K. Rosenthal. Med. Coll. of Wisconsin, Milwaukee, WI, USA
Calcium-containing crystals including calcium pyrophosphate ( CPP)
and basic calcium phosphate (BCP) crystals are common components of
osteoarthritic (OA) synovial ﬂuid. Similarly, histologic examination of
tissue from unselected patients undergoing total joint replacement for
OA demonstrate BCP crystal deposition in 100% and CPP crystals in 20-
30%. Despite their high prevalence, the role of these crystals in OA
remains poorly understood.
New ﬁndings relevant to our understanding of crystal formation and
the pathogenesis of OA will be discussed. For example, the role of
extracellular ATP in OA and crystal formation, the critical participation
of ANK protein in cartilage calciﬁcation, and some novel work on for-
mation and release of articular cartilage vesicles will be presented. The
impact of these studies on available and emerging management strat-
egies will be addressed. The cause/effect relationship between OA and
calcium-containing crystal deposition is complex and multifactorial.
While many risk factors and some etiologic factors are shared, it is clear
that calcium-containing crystals contribute to cartilage damage in OA.
CPP crystals produce articular inﬂammation likely by stimulating
components of the innate immune system. The inﬂammatory potential
of BCP crystals as well as the mechanisms involved are much less well
understood. These pathways will be discussed in the context of the
increasing evidence that inﬂammatory processes play a critical role in
OA. BCP and CPP crystals also produce non-inﬂammatory tissue damage
by directly interacting with synovial cells and chondrocytes, and their
presence causes alterations in tissue mechanics which can contribute to
joint dysfunction and pain.
Improved recognition of these crystals in the clinical setting and better
appreciation of their etiological role in OA will ultimately result in
better treatments for all patients with degenerative arthritis.
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CYTOKINE CROSSTALK IN INFLAMMATORY AND MECHANICAL
STRESS MECHANISMS IN OSTEOARTHRITIS
M.B. Goldring y,z. yHosp. for Special Surgery, New York, NY, USA; zWeill
Cornell Med. Coll., New York, NY, USA
Osteoarthritis (OA) is a whole joint disease, in which thinning and loss
of cartilage is a critical determinant in OA progression. The disruption of
cartilage homeostasis due to multiple potential causes, related to aging,
genetic susceptibility, trauma, or disordered metabolism, is associated
with profound phenotypic modiﬁcations of chondrocytes. Early
changes involve disruption of the pericellular matrix through signaling
events mediated by chondrocyte receptors such as discoidin domain
receptor-2 (DDR-2). Studies in my laboratory address the mechanisms
of gene regulation by which stress- and inﬂammation-induced signals
induce expression of matrix metalloproteinase 13 (MMP-13), the piv-
otal collagen-degrading proteinase that marks OA progression, as well
as other catabolic and inﬂammatory responses in cartilage and other
joint tissues. Common mediators of these processes, which are also
involved in mechanotransduction in OA cartilage, include IKKs and
MAPKs. These pathways converge on transcriptional regulation by NF-
kB, Elf3, C/EBPb, Runx2, and hypoxia-inducible factor (HIF) 2a. The
IKKb-driven canonical NF-kB signaling pathway coordinates mechan-
ical, inﬂammatory, and oxidative stress-activated events leading normal
chondrocytes to become activated, promoting catabolic events. IKKa,
the non-canonical IKK that also participates in canonical signaling,
functions as a positive mediator chondrocyte differentiation to a
hypertrophic-like phenotype independent of its kinase activity. NF-kB
signaling is among the gene signatures in post-traumatic OA and aging
models and human OA chondrocytes exhibit prominent epigenomic
alterations, such as de-methylation of CpG sites in the promoters of
MMP13, IL1B, and other key genes. These alterations lead to de-regu-
lated gene expression, exacerbated, and sustained NF-kB activation and
production of proteinases and inﬂammatory mediators, all of which can
be modeled in vitro by IL-1b stimulation. We are currently proﬁling
temporal and spatial changes in gene expression and microRNAs over
the course of disease initiation and progression in mouse models of OA
using novel mouse strains with inducible, cartilage-speciﬁc deletion of
IKKa and IKKb, in addition to the Runx2þ/- mouse, which is protected
from OA, and the Col11a1þ/- chondrodysplasia mouse that develops
accelerated OAwith aging. We have also generated novel mouse strains
